Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b

Open access
Vennin, Constance, Spruyt, Nathalie, Dahmani, Fatima, Julien, Sylvain, Bertucci, François, Finetti, Pascal, Chassat, Thierry, Bourette, Roland P., Le Bourhis, Xuefen, Adriaenssens, Eric·2015·Oncotarget

Abstract

// Constance Vennin 1,2 , Nathalie Spruyt 3 , Fatima Dahmani 3 , Sylvain Julien 1,2 , François Bertucci 4 , Pascal Finetti 4 , Thierry Chassat 5 , Roland P. Bourette 3 , Xuefen Le Bourhis 1,2 and Eric Adriaenssens 1,2 1 INSERM U908, Cell Plasticity and Cancer, F-59655, Villeneuve d’Ascq, France 2 University of Lille, F-59655, Villeneuve d’Ascq, France 3 CNRS UMR 8161, F-59021, Lille, France 4 Paoli-Calmettes Institute, Aix -Marseille University, F-13009, Marseille, France 5 PLETHA, Institut Pasteur Lille, F-59019, Lille, France Correspondence to: Eric Adriaenssens, email: // Keywords : H19, miRNA, breast cancer, CBL, tyrosine kinase receptor Received : April 28, 2015 Accepted : July 16, 2015 Published : July 22, 2015 Abstract H19 is a long non-coding RNA precursor of miR-675microRNA. H19 is increasingly described to play key roles in the progression and metastasis of cancers from different tissue origins. We have previously shown that the H19 gene is activated by growth factors and increases breast cancer cell invasion. In this study, we established H19 /miR-675 ectopic expression models of MDA-MB-231 breast cancer cells to further investigate the underlying mechanisms of H19 oncogenic action. We showed that overexpression of H19 /miR-675 enhanced the aggressive phenotype of breast cancer cells including increased cell proliferation and migration in vitro , and increased tumor growth and metastasis in vivo . Moreover, we identified ubiquitin ligase E3 family (c-Cbl and Cbl-b) as direct targets of miR-675 in breast cancer cells. Using a luciferase assay, we demonstrated that H19 , through its microRNA, decreased both c-Cbl and Cbl-b expression in all breast cancer cell lines tested. Thus, by directly binding c-Cbl and Cbl-b mRNA, miR-675 increased the stability and the activation of EGFR and c-Met, leading to sustained activation of Akt and Erk as well as enhanced cell proliferation and migration. Our data describe a novel mechanism of protumoral action of H19 in breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4976

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 202

Metadata

Authors
Vennin, C., Spruyt, N., Dahmani, F., Julien, S., Bertucci, F., Finetti, P., Chassat, T., Bourette, R. P., Le Bourhis, X., & Adriaenssens, E.
Venue
Oncotarget
Published
2015-07-22
Volume
6
Issue
30
Pages
29209-29223
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2139766730
Cited by
202
References
1
FWCI
9.52
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. https://app.cochat.ai/papers/10.18632/oncotarget.4976
The paper
Vennin, C., Spruyt, N., Dahmani, F., Julien, S., Bertucci, F., Finetti, P., Chassat, T., Bourette, R. P., Le Bourhis, X., & Adriaenssens, E. (2015). H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. https://doi.org/10.18632/oncotarget.4976

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.